Esophageal melanoma
diseaseOn this page
Also known as esophagus melanomaesophagus melanoma (disease)melanoma (disease) of esophagusmelanoma (disease) of oesophagusmelanoma of esophagusmelanoma of oesophagusmelanoma of the esophagusmelanoma of the oesophagusmucosal melanoma of the esophagusmucosal melanoma of the oesophagusoesophagus melanoma (disease)
Summary
Esophageal melanoma (MONDO:0001192) is a cancer and 1 clinical trial. Top therapeutic interventions include cabozantinib. A subtype of esophageal cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | esophageal melanoma |
| Mondo ID | MONDO:0001192 |
| DOID | DOID:1108 |
| ICD-11 | 1371529838 |
| NCIT | C5707 |
| UMLS | C1333460 |
| MedGen | 272590 |
| GARD | 0027569 |
| Anatomy (UBERON) | UBERON:0001043 |
| Is cancer (heuristic) | yes |
Also known as: esophageal melanoma · esophagus melanoma · esophagus melanoma (disease) · melanoma (disease) of esophagus · melanoma (disease) of oesophagus · melanoma of esophagus · melanoma of oesophagus · melanoma of the esophagus · melanoma of the oesophagus · mucosal melanoma of the esophagus · mucosal melanoma of the oesophagus · oesophagus melanoma (disease)
Disease family
This is a subtype of esophageal cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › esophageal cancer › esophageal melanoma
Related subtypes (6): esophagus lymphoma, esophagus sarcoma, carcinoma of esophagus, malignant neoplasm of abdominal esophagus, malignant neoplasm of thoracic esophagus, malignant neoplasm of cervical esophagus
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05111574 | PHASE2 | RECRUITING | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CABOZANTINIB | 4 | 3 |
Related Atlas pages
- Drugs: Cabozantinib